| Previous Close | 2,543,000.00 |
| Open | 2,525,000.00 |
| Bid | 2,535,000.00 x |
| Ask | 2,535,000.00 x |
| Day's Range | 2,525,000.00 - 2,538,000.00 |
| 52 Week Range | 1,456,000.00 - 2,566,000.00 |
| Volume | 16,942 |
| Avg. Volume | 224,693 |
| Market Cap | 319.57T |
| Beta | 0.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Jul 27, 2017 |
| Dividend & Yield | 25.45 (1.22%) |
| Ex-Dividend Date | 2016-12-28 |
| 1y Target Est | N/A |
- The Wall Street Journal•42 minutes ago
[$$] Samsung Releases Arthritis Drug in First Foray Into U.S. Pharmaceuticals
South Korea’s Samsung conglomerate, best known for its smartphones and televisions, will make available in the U.S. its lower-price copy of Johnson & Johnson’s blockbuster arthritis drug Remicade.
- ZDNet•7 hours ago
Samsung Galaxy S8 Active shown off in leaked photos with flat display
Samsung's Active version of the Galaxy S8 is said to feature a flat 5.8-inch display, Bixby button, and Android O.
- Reuters•7 hours ago
iPhone supplier AMS raises mid-term revenue target
Chipmaker AMS, which supplies components to Apple and Samsung Electronics among others, on Monday raised its mid-term revenue growth target, thanks to increased customer forecasts and a higher revenue pipeline. The company said in April it might raise mid-term revenue growth target as it expected significant ramp-ups in its consumer business in the second half of the year. AMS said its revenue growth target for 2016-2019 would rise to a more than 40 percent compound annual growth rate and it confirmed an adjusted core profit margin target of 30 percent from 2019 onwards.
